EP2903614A4 - Novel compounds, their synthesis and their uses - Google Patents
Novel compounds, their synthesis and their usesInfo
- Publication number
- EP2903614A4 EP2903614A4 EP13844254.6A EP13844254A EP2903614A4 EP 2903614 A4 EP2903614 A4 EP 2903614A4 EP 13844254 A EP13844254 A EP 13844254A EP 2903614 A4 EP2903614 A4 EP 2903614A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- synthesis
- novel compounds
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000015572 biosynthetic process Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Anesthesiology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN3114DE2012 | 2012-10-05 | ||
| PCT/IN2013/000607 WO2014054058A2 (en) | 2012-10-05 | 2013-10-07 | Novel compounds, their synthesis and their uses |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| EP2903614A2 EP2903614A2 (en) | 2015-08-12 |
| EP2903614A4 true EP2903614A4 (en) | 2016-07-20 |
| EP2903614B1 EP2903614B1 (en) | 2021-09-29 |
Family
ID=50435536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP13844254.6A Active EP2903614B1 (en) | 2012-10-05 | 2013-10-07 | Novel compounds, their synthesis and their uses |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9556156B2 (en) |
| EP (1) | EP2903614B1 (en) |
| JP (1) | JP6621329B2 (en) |
| CN (2) | CN104812388A (en) |
| ES (1) | ES2899694T3 (en) |
| WO (1) | WO2014054058A2 (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9487500B2 (en) | 2012-10-04 | 2016-11-08 | Inhibikase Therapeutics, Inc. | Compounds and compositions thereof |
| CN109153639B (en) * | 2016-03-14 | 2022-07-29 | 斯法尔制药私人有限公司 | Trigonelline compounds |
| EP3609882B1 (en) | 2017-03-17 | 2022-07-13 | Cardio Therapeutics Pty Ltd | Heterocyclic inhibitors of pcsk9 |
| PL238932B1 (en) * | 2017-12-31 | 2021-10-18 | Univ Jagiellonski | Derivatives of pyridinium salts, method for releasing MNA and their application |
| US11136295B2 (en) * | 2018-10-29 | 2021-10-05 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
| US11628178B2 (en) | 2019-03-26 | 2023-04-18 | Epalex Corporation | Fospropofol methods and compositions |
| US11478490B1 (en) | 2021-03-30 | 2022-10-25 | Epalex Corporation | Fospropofol formulations |
| US11547714B2 (en) | 2020-02-05 | 2023-01-10 | Epalex Corporation | Fospropofol salts, methods and compositions |
| US11439653B1 (en) | 2021-03-30 | 2022-09-13 | Epalex Corporation | Fospropofol formulations |
| EP3956287A4 (en) * | 2019-04-17 | 2022-12-14 | Ixchel Pharma, LLC | Prodrugs of monomethyl fumarate |
| CN116751132B (en) * | 2023-05-25 | 2024-08-09 | 郑州大学 | Brain-targeted propofol prodrug, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160099A (en) * | 1974-06-24 | 1979-07-03 | Interx Research Corporation | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives |
| WO2012137225A1 (en) * | 2011-04-08 | 2012-10-11 | Sphaera Pharma Pvt. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| WO2013016668A2 (en) * | 2011-07-28 | 2013-01-31 | Kempharm Inc. | Methylphenidate-prodrugs, processes of making and using the same |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989711A (en) * | 1975-09-22 | 1976-11-02 | Interx Research Corporation | Soft quaternary surface active agents exhibiting antibacterial activity |
| DK534178A (en) * | 1977-12-16 | 1979-06-17 | Interx Research Corp | ANTICHOLINERGIC AGENTS WITH SECTIONING EFFECT |
| US4361571A (en) * | 1981-01-21 | 1982-11-30 | Scott Eugene J Van | 3-Carbamoyl-6-aminopyridinium and analogues, and their use in treating skin disorders |
| US5525727A (en) * | 1982-05-18 | 1996-06-11 | University Of Florida | Brain-specific drug delivery |
| US4428935A (en) * | 1982-05-24 | 1984-01-31 | Pfizer Inc. | Penicillanic acid dioxide prodrug |
| GB9607219D0 (en) * | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
| JP2001508399A (en) * | 1997-03-26 | 2001-06-26 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | Indole derivatives as 5-HT receptor antagonists |
| CA2351075A1 (en) * | 1999-10-06 | 2001-04-12 | Torrent Pharmaceuticals Ltd. | Pyridinium derivatives for the treatment of diabetic and aging-related vascular complications |
-
2013
- 2013-10-07 CN CN201380060822.2A patent/CN104812388A/en active Pending
- 2013-10-07 WO PCT/IN2013/000607 patent/WO2014054058A2/en active Application Filing
- 2013-10-07 JP JP2015535173A patent/JP6621329B2/en active Active
- 2013-10-07 ES ES13844254T patent/ES2899694T3/en active Active
- 2013-10-07 US US14/433,485 patent/US9556156B2/en active Active
- 2013-10-07 EP EP13844254.6A patent/EP2903614B1/en active Active
- 2013-10-07 CN CN201910678793.5A patent/CN110526864A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4160099A (en) * | 1974-06-24 | 1979-07-03 | Interx Research Corporation | Labile, non-heterocyclic quaternary ammonium salt/esters as transient derivatives |
| WO2012137225A1 (en) * | 2011-04-08 | 2012-10-11 | Sphaera Pharma Pvt. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| WO2013016668A2 (en) * | 2011-07-28 | 2013-01-31 | Kempharm Inc. | Methylphenidate-prodrugs, processes of making and using the same |
Non-Patent Citations (5)
| Title |
|---|
| BODOR N: "Soft drugs. 1. Labile quaternary ammonium salts as antimicrobials", JOURNAL OF MEDICINAL AND PHARMACEUTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, US, vol. 23, no. 5, 1 January 1980 (1980-01-01), pages 469 - 474, XP002199291, DOI: 10.1021/JM00179A001 * |
| PITMAN I H: "PRO-DRUGS OF AMIDES, IMIDES, AND AMINES", MEDICINAL RESEARCH REVIEWS, NEW YORK, NY, US, vol. 1, no. 2, 1 January 1981 (1981-01-01), pages 189 - 214, XP000652623, ISSN: 0198-6325 * |
| See also references of WO2014054058A2 * |
| SIMPLÍCIO ANA L ET AL: "Prodrugs for amines", MOLECULES, MOLECULAR DIVERSITY PRESERVATION INTERNATIONAL, BASEL, CH, vol. 13, no. 3, 1 January 2008 (2008-01-01), pages 519 - 547, XP002503564, ISSN: 1420-3049, DOI: 10.3390/MOLECULES13030519 * |
| YANG D ET AL: "The antimicrobial activity of liposomal lauric acids against Propionibacterium acnes", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 30, no. 30, 1 October 2009 (2009-10-01), pages 6035 - 6040, XP026524669, ISSN: 0142-9612, [retrieved on 20090808], DOI: 10.1016/J.BIOMATERIALS.2009.07.033 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104812388A (en) | 2015-07-29 |
| CN110526864A (en) | 2019-12-03 |
| JP2015535849A (en) | 2015-12-17 |
| US9556156B2 (en) | 2017-01-31 |
| WO2014054058A3 (en) | 2014-09-12 |
| EP2903614B1 (en) | 2021-09-29 |
| WO2014054058A8 (en) | 2015-04-09 |
| JP6621329B2 (en) | 2019-12-18 |
| WO2014054058A2 (en) | 2014-04-10 |
| US20150252027A1 (en) | 2015-09-10 |
| ES2899694T3 (en) | 2022-03-14 |
| EP2903614A2 (en) | 2015-08-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201207406D0 (en) | Novel compounds | |
| HK1204797A1 (en) | Novel anti-siglec15 antibody -siglec-15 | |
| EP2922550A4 (en) | Novel compounds | |
| EP2903614A4 (en) | Novel compounds, their synthesis and their uses | |
| EP2900829A4 (en) | Glycoconjugate synthesis | |
| EP2922549A4 (en) | Novel compounds | |
| EP2935168A4 (en) | Synthesis of 3,3,3-trifluoropropyne | |
| EP2922547A4 (en) | Novel compounds | |
| GB201216800D0 (en) | Novel use | |
| HK1211486A1 (en) | Novel uses | |
| EP2903979A4 (en) | Novel compounds, their preparation and their uses | |
| GB201217313D0 (en) | Block copolymer synthesis | |
| GB201218352D0 (en) | Compounds and their synthesis | |
| GB201207392D0 (en) | Novel compounds | |
| IL237542B (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| IL280316B (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| HK1210437A1 (en) | Antimicrobial compounds, their synthesis and applications thereof | |
| HK1202876A1 (en) | Improved synthesis | |
| IL237540A0 (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| IL237538A0 (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| IL237539A0 (en) | Bolaamphiphilic compounds, compositions and uses thereof | |
| GB201212463D0 (en) | Novel use | |
| AU2012902119A0 (en) | Improved synthesis | |
| GB201222528D0 (en) | Novel uses | |
| GB201222391D0 (en) | Novel Uses |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20150506 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 401/14 20060101AFI20160215BHEP Ipc: A61K 31/4425 20060101ALI20160215BHEP Ipc: C07D 471/14 20060101ALI20160215BHEP Ipc: C07D 213/82 20060101ALI20160215BHEP Ipc: C07D 487/04 20060101ALI20160215BHEP Ipc: C07D 405/14 20060101ALI20160215BHEP |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R079 Ref document number: 602013079478 Country of ref document: DE Free format text: PREVIOUS MAIN CLASS: A61K0031442500 Ipc: C07D0401140000 |
|
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20160622 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07D 405/14 20060101ALI20160616BHEP Ipc: C07D 401/14 20060101AFI20160616BHEP Ipc: C07D 213/82 20060101ALI20160616BHEP Ipc: A61K 31/4425 20060101ALI20160616BHEP Ipc: C07D 471/14 20060101ALI20160616BHEP Ipc: C07D 487/04 20060101ALI20160616BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| 17Q | First examination report despatched |
Effective date: 20170516 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
| GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
| INTG | Intention to grant announced |
Effective date: 20210414 |
|
| RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: SPHAERA PHARMA PTE. LTD |
|
| GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
| GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
| AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602013079478 Country of ref document: DE |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1434112 Country of ref document: AT Kind code of ref document: T Effective date: 20211015 |
|
| REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
| REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
| REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG9D |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211229 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211229 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1434112 Country of ref document: AT Kind code of ref document: T Effective date: 20210929 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20211230 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2899694 Country of ref document: ES Kind code of ref document: T3 Effective date: 20220314 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220129 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20220131 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20211031 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602013079478 Country of ref document: DE |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211007 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 |
|
| PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211031 |
|
| 26N | No opposition filed |
Effective date: 20220630 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20211007 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20131007 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230530 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240206 Year of fee payment: 11 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240124 Year of fee payment: 11 Ref country code: GB Payment date: 20240117 Year of fee payment: 11 |
|
| PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20240117 Year of fee payment: 11 Ref country code: IT Payment date: 20240118 Year of fee payment: 11 Ref country code: FR Payment date: 20240117 Year of fee payment: 11 |
|
| REG | Reference to a national code |
Ref country code: DE Ref legal event code: R081 Ref document number: 602013079478 Country of ref document: DE Owner name: PIVOT HOLDING LLC, LAS VEGAS, US Free format text: FORMER OWNER: SPHAERA PHARMA PTE. LTD, SINGAPORE, SG |
|
| REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E Free format text: REGISTERED BETWEEN 20240704 AND 20240710 |
|
| PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210929 |
|
| REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A Owner name: PIVOT HOLDING LLC Effective date: 20241028 |